Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients

Orfeu M Buxton,1-4 Milena K Pavlova,1,5 Shawn P O’Connor,1 Wei Wang,1,2 John W Winkelman1,6 1Division of Sleep Medicine, Harvard Medical School, 2Department of Medicine, Brigham and Women’s Hospital, 3Department of Social and Behavioral Sciences, Harvard School of Public Health,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Buxton OM, Pavlova MK, O'Connor SP, Wang W, Winkelman JW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	primary insomnia sleep duration metabolism IVGTT insulin sensitivity diabetes eszopiclone wake after sleep onset Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495
Acceso en línea:	https://doaj.org/article/16a9b0be403c45298f290b9d6943cc67
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16a9b0be403c45298f290b9d6943cc67
record_format	dspace
spelling	oai:doaj.org-article:16a9b0be403c45298f290b9d6943cc672021-12-02T00:51:23ZLack of change in glucose metabolism in eszopiclone-treated primary insomnia patients1179-1608https://doaj.org/article/16a9b0be403c45298f290b9d6943cc672017-07-01T00:00:00Zhttps://www.dovepress.com/lack-of-change-in-glucose-metabolism-in-eszopiclone-treated-primary-in-peer-reviewed-article-NSShttps://doaj.org/toc/1179-1608Orfeu M Buxton,1-4 Milena K Pavlova,1,5 Shawn P O’Connor,1 Wei Wang,1,2 John W Winkelman1,6 1Division of Sleep Medicine, Harvard Medical School, 2Department of Medicine, Brigham and Women’s Hospital, 3Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, 4Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, 5Department of Neurology, Brigham and Women’s Hospital, 6Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA Study objectives: Primary insomnia (PI) may increase diabetes risk. We tested the hypothesis that the effects of PI on glucose metabolism could be improved by 2 months of pharmacological treatment.Methods: Adult men and women meeting clinical criteria for PI were studied (n=20, body mass index 25.1±2.7 kg/m2, age 39.7±7.9) in a randomized, double-blind, placebo-controlled clinical trial. The study consisted of two 1-day inpatient admissions to a General Clinical Research Center separated by 2 months of at-home treatment with 3 mg eszopiclone or placebo. During inpatient admissions, each subject underwent two intravenous glucose tolerance tests (IVGTTs) pre- and post-treatment. Diet was controlled for micro- and macro-nutrient content and calories on the day prior to pre- and post-treatment IVGTTs. Subjects were randomized following completion of the initial IVGTT to take either placebo or eszopiclone 30 min prior to bedtime at home for 2 months.Results: Two-month eszopiclone treatment did not change insulin sensitivity, glucose tolerance, or any of the sleep measures significantly, compared with placebo. Changes in glycated hemoglobin (HbA1c, clinical measure of glycemic control) were correlated with changes in diary-reported total sleep time in the eszopiclone group (r=0.66, p=0.0360), and in the combined groups’ data (r=0.55, p=0.0125). Changes in polysomnography-measured wake after sleep onset, a hallmark of PI, were positively related to changes in IVGTT-derived glucose effectiveness, or non-insulin-mediated glucose uptake.Conclusion: Treatment with 3 mg eszopiclone for 2 months, compared with placebo, did not significantly influence either sleep or measures of diabetes risk in this preliminary study. Keywords: primary insomnia, sleep duration, metabolism, IVGTT, insulin sensitivity, diabetes, eszopiclone, wake after sleep onsetBuxton OMPavlova MKO'Connor SPWang WWinkelman JWDove Medical Pressarticleprimary insomniasleep durationmetabolismIVGTTinsulin sensitivitydiabeteseszopiclonewake after sleep onsetPsychiatryRC435-571Neurophysiology and neuropsychologyQP351-495ENNature and Science of Sleep, Vol Volume 9, Pp 187-198 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	primary insomnia sleep duration metabolism IVGTT insulin sensitivity diabetes eszopiclone wake after sleep onset Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495
spellingShingle	primary insomnia sleep duration metabolism IVGTT insulin sensitivity diabetes eszopiclone wake after sleep onset Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495 Buxton OM Pavlova MK O'Connor SP Wang W Winkelman JW Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients
description	Orfeu M Buxton,1-4 Milena K Pavlova,1,5 Shawn P O’Connor,1 Wei Wang,1,2 John W Winkelman1,6 1Division of Sleep Medicine, Harvard Medical School, 2Department of Medicine, Brigham and Women’s Hospital, 3Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, 4Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, 5Department of Neurology, Brigham and Women’s Hospital, 6Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA Study objectives: Primary insomnia (PI) may increase diabetes risk. We tested the hypothesis that the effects of PI on glucose metabolism could be improved by 2 months of pharmacological treatment.Methods: Adult men and women meeting clinical criteria for PI were studied (n=20, body mass index 25.1±2.7 kg/m2, age 39.7±7.9) in a randomized, double-blind, placebo-controlled clinical trial. The study consisted of two 1-day inpatient admissions to a General Clinical Research Center separated by 2 months of at-home treatment with 3 mg eszopiclone or placebo. During inpatient admissions, each subject underwent two intravenous glucose tolerance tests (IVGTTs) pre- and post-treatment. Diet was controlled for micro- and macro-nutrient content and calories on the day prior to pre- and post-treatment IVGTTs. Subjects were randomized following completion of the initial IVGTT to take either placebo or eszopiclone 30 min prior to bedtime at home for 2 months.Results: Two-month eszopiclone treatment did not change insulin sensitivity, glucose tolerance, or any of the sleep measures significantly, compared with placebo. Changes in glycated hemoglobin (HbA1c, clinical measure of glycemic control) were correlated with changes in diary-reported total sleep time in the eszopiclone group (r=0.66, p=0.0360), and in the combined groups’ data (r=0.55, p=0.0125). Changes in polysomnography-measured wake after sleep onset, a hallmark of PI, were positively related to changes in IVGTT-derived glucose effectiveness, or non-insulin-mediated glucose uptake.Conclusion: Treatment with 3 mg eszopiclone for 2 months, compared with placebo, did not significantly influence either sleep or measures of diabetes risk in this preliminary study. Keywords: primary insomnia, sleep duration, metabolism, IVGTT, insulin sensitivity, diabetes, eszopiclone, wake after sleep onset
format	article
author	Buxton OM Pavlova MK O'Connor SP Wang W Winkelman JW
author_facet	Buxton OM Pavlova MK O'Connor SP Wang W Winkelman JW
author_sort	Buxton OM
title	Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients
title_short	Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients
title_full	Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients
title_fullStr	Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients
title_full_unstemmed	Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients
title_sort	lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/16a9b0be403c45298f290b9d6943cc67
work_keys_str_mv	AT buxtonom lackofchangeinglucosemetabolismineszopiclonetreatedprimaryinsomniapatients AT pavlovamk lackofchangeinglucosemetabolismineszopiclonetreatedprimaryinsomniapatients AT oconnorsp lackofchangeinglucosemetabolismineszopiclonetreatedprimaryinsomniapatients AT wangw lackofchangeinglucosemetabolismineszopiclonetreatedprimaryinsomniapatients AT winkelmanjw lackofchangeinglucosemetabolismineszopiclonetreatedprimaryinsomniapatients
_version_	1718403422044028928

Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients

Ejemplares similares